Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
暂无分享,去创建一个
Michelle R. Arkin | Joseph Mulvaney | Jiri Gut | Steven Chen | J. Gut | M. Arkin | K. Ang | Chiung-Kuang J. Chen | J. McKerrow | C. M. Calvet | Steven Chen | Jonathan B. Johnston | J. Engel | Chiung-Kuang Chen | James H. McKerrow | Larissa M. Podust | Juan C. Engel | Kenny K. H. Ang | Shamila S. Gunatilleke | Claudia M. Calvet | Grigori Erenburg | L. Podust | G. Erenburg | J. Mulvaney
[1] M. Taplin,et al. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer , 2012, Current opinion in oncology.
[2] D. Marriott,et al. Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.
[3] P. Brown,et al. Aromatase inhibitors and breast cancer prevention , 2012, Expert opinion on pharmacotherapy.
[4] R. Robitaille,et al. Concentration of Antifungal Agents within Host Cell Membranes: a New Paradigm Governing the Efficacy of Prophylaxis , 2011, Antimicrobial Agents and Chemotherapy.
[5] T. Zaoutis,et al. Posaconazole: when and how? The clinician’s view , 2011, Mycoses.
[6] O. Cars,et al. Posaconazole in Human Serum: a Greater Pharmacodynamic Effect than Predicted by the Non-Protein-Bound Serum Concentration , 2011, Antimicrobial Agents and Chemotherapy.
[7] F. Buckner,et al. Advances in Chagas disease drug development: 2009–2010 , 2010, Current opinion in infectious diseases.
[8] Celia A. Schiffer,et al. Molecular Basis for Drug Resistance in HIV-1 Protease , 2010, Viruses.
[9] J. Urbina,et al. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. , 2010, International journal of antimicrobial agents.
[10] J. Urbina. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. , 2010, Acta tropica.
[11] Michelle R. Arkin,et al. Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.
[12] M. Waterman,et al. Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruzi* , 2010, The Journal of Biological Chemistry.
[13] J. Heeres,et al. Conazoles , 2010, Molecules.
[14] M. Gelb,et al. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. , 2010, Journal of medicinal chemistry.
[15] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[16] Matthew P. Jacobson,et al. A Nonazole CYP51 Inhibitor Cures Chagas’ Disease in a Mouse Model of Acute Infection , 2010, Antimicrobial Agents and Chemotherapy.
[17] Siegfried S. F. Leung,et al. Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole , 2010, PLoS neglected tropical diseases.
[18] G. Espinosa,et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. , 2010, The American journal of tropical medicine and hygiene.
[19] J. V. Kries,et al. Identification of Small‐Molecule Scaffolds for P450 Inhibitors , 2010, Current protocols in microbiology.
[20] M. Gelb,et al. Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. , 2009, Bioorganic & medicinal chemistry letters.
[21] P. Fontana,et al. Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. , 2009, Future cardiology.
[22] W. de Souza,et al. Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs , 2009, Interdisciplinary perspectives on infectious diseases.
[23] I D Kerr,et al. Two approaches to discovering and developing new drugs for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.
[24] J. Urbina,et al. Ergosterol biosynthesis and drug development for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.
[25] S. Costa-de-Oliveira,et al. Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles. , 2009, FEMS yeast research.
[26] M. Gelb,et al. Rational modification of a candidate cancer drug for use against Chagas disease. , 2009, Journal of medicinal chemistry.
[27] K. Ang,et al. Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit , 2009, PLoS neglected tropical diseases.
[28] C. Wasternack,et al. Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution , 2008, Biological chemistry.
[29] J. Hardwick. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. , 2008, Biochemical pharmacology.
[30] E. Mellado,et al. Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus , 2008, Antimicrobial Agents and Chemotherapy.
[31] M. Waterman,et al. Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography , 2007, Antimicrobial Agents and Chemotherapy.
[32] N. Galanti,et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. , 2007, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[33] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[34] R. Gazzinelli,et al. The Anti-Trypanosoma cruzi Activity of Posaconazole in a Murine Model of Acute Chagas' Disease Is Less Dependent on Gamma Interferon than That of Benznidazole , 2007, Antimicrobial Agents and Chemotherapy.
[35] Solomon Nwaka,et al. Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.
[36] David Rogers,et al. Cheminformatics analysis and learning in a data pipelining environment , 2006, Molecular Diversity.
[37] M. Gelb,et al. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. , 2005, Journal of medicinal chemistry.
[38] E. Mellado,et al. Substitutions at Methionine 220 in the 14α-Sterol Demethylase (Cyp51A) of Aspergillus fumigatus Are Responsible for Resistance In Vitro to Azole Antifungal Drugs , 2004, Antimicrobial Agents and Chemotherapy.
[39] M. Verdonk,et al. Structure-guided fragment screening for lead discovery. , 2004, Current opinion in drug discovery & development.
[40] Katherine A Brown,et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. , 2003, Molecular and biochemical parasitology.
[41] D. Rice,et al. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. , 2003, Molecular and biochemical parasitology.
[42] D. Loebenberg,et al. Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-Demethylase , 2003, Antimicrobial Agents and Chemotherapy.
[43] Tudor I. Oprea. Current trends in lead discovery: Are we looking for the appropriate properties? , 2002, J. Comput. Aided Mol. Des..
[44] J. Urbina,et al. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. , 1999, Molecular and biochemical parasitology.
[45] J. Urbina. Chemotherapy of Chagas’ disease: the how and the why , 1999, Journal of Molecular Medicine.
[46] J. McKerrow,et al. Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection , 1998, Journal of Experimental Medicine.
[47] P. Wincker,et al. Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum)cruzi: In Vitro and In Vivo Studies , 1998, Antimicrobial Agents and Chemotherapy.
[48] Marvin Waldman,et al. Optimization and visualization of molecular diversity of combinatorial libraries , 1996, Molecular Diversity.
[49] P. Wincker,et al. Cure of Short- and Long-Term Experimental Chagas' Disease Using D0870 , 1996, Science.
[50] J. Urbina,et al. Antiproliferative Effects and Mechanism of Action of ICI 195,739, a Novel Bis-Triazole Derivative, on Epimastigotes and Amastigotes of Trypanosoma (Schizotrypanum) cruzi , 1992, Antimicrobial Agents and Chemotherapy.
[51] Peter J. Rousseeuw,et al. Finding Groups in Data: An Introduction to Cluster Analysis , 1990 .
[52] J. Urbina,et al. Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi , 1991, Antimicrobial Agents and Chemotherapy.
[53] W. de Souza,et al. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi , 1990, Antimicrobial Agents and Chemotherapy.
[54] R. Isturiz,et al. Chagas Disease , 2021, Neglected Tropical Diseases.
[55] J. Dvorak,et al. Trypanosoma cruzi: biological characterization of clones derived from chronic chagasic patients. II. Quantitative analysis of the intracellular cycle. , 1985, The Journal of protozoology.
[56] J F Morrison,et al. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. , 1969, Biochimica et biophysica acta.
[57] R. Estabrook,et al. Spectral studies of drug interaction with hepatic microsomal cytochrome. , 1967, Molecular pharmacology.
[58] T. Omura,et al. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.
[59] Carlos Chagas,et al. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem , 1909 .
[60] P. Ortiz de Montellano,et al. Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1. , 2011, Bioorganic & medicinal chemistry letters.
[61] F. Buckner,et al. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. , 2008, Advances in experimental medicine and biology.
[62] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[63] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.